These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21216118)

  • 1. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B.
    Eser Karlidag G; Karlidag T; Demirdag K; Keles E
    Auris Nasus Larynx; 2011 Jun; 38(3):312-8. PubMed ID: 21216118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
    Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
    Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
    Vassiliadis T; Tziomalos K; Patsiaoura K; Zagris T; Giouleme O; Soufleris K; Grammatikos N; Theodoropoulos K; Mpoumponaris A; Dona K; Zezos P; Nikolaidis N; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1582-8. PubMed ID: 17683500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
    Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP
    Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.
    Zhang YL; Zhang J; Cui LY
    Hepatogastroenterology; 2015; 62(137):133-9. PubMed ID: 25911883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.
    Sypsa VA; Mimidis K; Tassopoulos NC; Chrysagis D; Vassiliadis T; Moulakakis A; Raptopoulou M; Haida C; Hatzakis A
    Hepatology; 2005 Jul; 42(1):77-85. PubMed ID: 15962284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
    Tian YL; Zhao W; Shen L; Liu W; Chang JB; Fang ZX; Yin WW; Wang L; Sun XB; Yang YJ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):806-10. PubMed ID: 17125604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection.
    Cindoruk M; Karakan T; Unal S
    J Clin Gastroenterol; 2007; 41(5):513-7. PubMed ID: 17450036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.
    Sprengers D; van der Molen RG; Binda R; Kusters JG; de Man RA; Niesters HG; Schalm SW; Janssen HL
    J Viral Hepat; 2007 Oct; 14(10):743-9. PubMed ID: 17875010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.
    Yalcin K; Degertekin H; Yildiz F; Celik Y
    Clin Infect Dis; 2003 Jun; 36(12):1516-22. PubMed ID: 12802750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.